Choice of Initial Oral Therapy for Pulmonary Arterial Hypertension: Age and Long-Term Survival

What is it about?

Several new classes of medicines can treat people afflicted with pulmonary arterial hypertension, but choices are not individualized. Here, we show that people young people survive longer when treated with an endothelin receptor antagonist as opposed to a phosphodiesterase-5 inhibitor.

Featured Image